modelN06DX01

Diagram of N06DX01

Extends from Pharmacokinetic.Models.PK_2C_enteral.

Information

name:Memantine
ATC code:N06DX01
route:oral
compartments:2
dosage:20mg
volume of distribution:430L
clearance:13.6L/h
other parameters in model implementation

Memantine is a moderate-affinity, uncompetitive NMDA receptor antagonist used primarily in the management of moderate to severe Alzheimer's disease. Memantine is approved and widely used for symptomatic treatment to slow cognitive decline in neurodegenerative conditions.

Pharmacokinetics

Pharmacokinetic parameters reported from healthy adult volunteers after a single oral administration.

References

  1. Kornhuber, J, et al., & Meineke, I (2007). Memantine pharmacotherapy: a naturalistic study using a population pharmacokinetic approach. Clinical pharmacokinetics 46(7) 599–612. DOI:10.2165/00003088-200746070-00005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/17596105

  2. Moritoyo, T, et al., & Nomoto, M (2012). Effect of renal impairment on the pharmacokinetics of memantine. Journal of pharmacological sciences 119(4) 324–329. DOI:10.1254/jphs.12043fp PUBMED:https://pubmed.ncbi.nlm.nih.gov/22863669

  3. Glass, OM, et al., & Schwartz, AC (2020). Considerations and Current Trends in the Management of the Geriatric Patient on a Consultation-Liaison Service. Current psychiatry reports 22(5) 21–None. DOI:10.1007/s11920-020-01147-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32285305

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance
Pharmacolibrary.Types.TransferRateka (from PK_2C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_2C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)